- Home
- SACH vs ANVS Comparison
SACH vs ANVS Comparison
Compare SACH & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- ANVS
- Stock Information
- Founded
- SACH 2010
- ANVS 2008
- Country
- SACH United States
- ANVS United States
- Employees
- SACH N/A
- ANVS N/A
- Industry
- SACH Real Estate Investment Trusts
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- ANVS Health Care
- Exchange
- SACH Nasdaq
- ANVS Nasdaq
- Market Cap
- SACH 54.4M
- ANVS 48.3M
- IPO Year
- SACH 2017
- ANVS 2020
- Fundamental
- Price
- SACH $1.25
- ANVS $2.43
- Analyst Decision
- SACH Hold
- ANVS Strong Buy
- Analyst Count
- SACH 4
- ANVS 4
- Target Price
- SACH $2.25
- ANVS $17.33
- AVG Volume (30 Days)
- SACH 246.4K
- ANVS 206.3K
- Earning Date
- SACH 11-13-2025
- ANVS 11-07-2025
- Dividend Yield
- SACH 15.94%
- ANVS N/A
- EPS Growth
- SACH N/A
- ANVS N/A
- EPS
- SACH N/A
- ANVS N/A
- Revenue
- SACH N/A
- ANVS N/A
- Revenue This Year
- SACH N/A
- ANVS N/A
- Revenue Next Year
- SACH $7.74
- ANVS N/A
- P/E Ratio
- SACH N/A
- ANVS N/A
- Revenue Growth
- SACH N/A
- ANVS N/A
- 52 Week Low
- SACH $0.80
- ANVS $1.11
- 52 Week High
- SACH $2.70
- ANVS $10.54
- Technical
- Relative Strength Index (RSI)
- SACH 52.08
- ANVS 49.50
- Support Level
- SACH $1.26
- ANVS $2.26
- Resistance Level
- SACH $1.35
- ANVS $2.52
- Average True Range (ATR)
- SACH 0.06
- ANVS 0.11
- MACD
- SACH 0.00
- ANVS 0.02
- Stochastic Oscillator
- SACH 44.74
- ANVS 71.94
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.